AWM
NBIX icon

Abound Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Abound Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$472 – 1203
2023
Q2 		$472 Buy
+5
New +$489 ﹤0.01% 863

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abound Wealth Management's NBIX Position: Q3 2023 in Review

Abound Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2023, closing a stake of 5 shares — an estimated $472 sold.

Abound Wealth Management first reported a position in NBIX in Q2 2023 and held it in 1 quarter. The position peaked at $472 in Q2 2023. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • Abound Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2023 after selling out during the quarter.
  • Abound Wealth Management sold 5 Neurocrine Biosciences shares in Q3 2023, an estimated $472.
  • Abound Wealth Management first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 1 quarter.
  • Abound Wealth Management's Neurocrine Biosciences position peaked at $472 in Q2 2023.
  • 511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Abound Wealth Management's 13F filing for Q3 2023, filed 8 Aug 2024.